e-ISSN: Pending
Negative / Null Result ReportOpen accessBiochemistry, Genetics and Molecular Biology· cited by 18

Retina-directed gene therapy: Achievements and remaining challenges

Josef Biber; Catharina Gandor; Elvir Bećirović; Stylianos Michalakis · 2025 · Pharmacology & Therapeutics

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Gene therapy is an innovative medical approach that offers new treatment options for congenital and acquired diseases by transferring, correcting, inactivating or regulating genes to supplement, replace or modify a gene function. The approval of voretigene neparvovec (Luxturna), a gene therapy for RPE65-associated retinopathy, has marked a milestone for the field of retinal gene therapy, but has also helped to accelerate the development of gene therapies for genetic diseases affecting other organs. Voretigene neparvovec is a vector based on adeno-associated virus (AAV) that delivers a function

Abstract by Josef Biber; Catharina Gandor; Elvir Bećirović; Stylianos Michalakis, Pharmacology & Therapeutics (2025) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1016/j.pharmthera.2025.108862